Signal Note — Healthcare PE

The Upcoding Reckoning

The $200 Number That Changes Everything for PE Healthcare

Healthcare PE | Reimbursement Reform | Human-Intel-Driven  ·  March 2026

The market reads MA rate compression as cyclical — CMS proposes low, the industry lobbies, CMS moderates. Every portfolio company with MA revenue concentration models a 4–6% annual increase because it always has been. On March 11, the Joint Economic Committee published a bipartisan finding that MA overpayments added $13.4 billion to Medicare Part B premiums in 2025 — roughly $200 per senior, per year. When the price of your reimbursement model is quantified on every voter's monthly bill by a Republican chairman, the political math for reversal has collapsed.

The Three-Front Squeeze

Three enforcement vectors are closing on the same revenue mechanism simultaneously.

Structural payment reform. CMS proposed in January to exclude unlinked chart review diagnoses from MA risk score calculations entirely, starting in 2027. Part C payments fall an estimated 1.53%. Final rule: April 6.

Legislative reinforcement. The No UPCODE Act (S.1105), introduced by Senators Cassidy (R-LA) and Merkley (D-OR), would legislatively ban chart review and HRA diagnoses from risk scoring. CBO projects $124 billion in savings over a decade.

Enforcement escalation. DOJ settled with Kaiser Permanente for a record $556 million over 500,000 diagnoses added without corresponding care. DOJ has active criminal and civil investigations into UnitedHealth's HouseCalls program. HHS-OIG estimates MA plans overcharge CMS $12.3 billion annually through home-based assessment upcoding alone.

When CMS eliminates the input, DOJ penalizes the output, and Congress quantifies the cost to voters — what remains of the business model built on the gap between the three?

Why the Conventional Wisdom Is Wrong

The standard read: "CMS always proposes low and moderates in the final rule. The industry will lobby this back."

Historically, true. Three things are different. First, the $200/senior number is bipartisan and granular — Schweikert (R) released a tracker by congressional district. Second, the No UPCODE Act has bipartisan sponsors and a CBO score — legislative backup if CMS moderates. Third, the Kaiser settlement and UnitedHealth criminal investigation are under the current administration. CMS may phase in changes. The direction is locked.

The IC Question

The question your LP will ask: "How much of our portfolio company margin was built on chart review revenue that CMS is about to exclude from risk scoring?"

The answer your IC needs: The risk is not a rate cut — it is a mechanism elimination. Disaggregate encounter-based coding margin from retrospective chart review margin. The former survives. The latter does not.

CMS finalizes 2027 rates on April 6. The exposure audit should happen before then, not after.

Who's Exposed

  • In-home health risk assessment companies — Inovalon (Nordic Capital), Episource, and the PE-backed HRA ecosystem built on retrospective chart review face architectural, not cyclical, revenue risk
  • MA-concentrated physician groups — flat rates (0.09% vs. modeled 4–6%) compress top line; chart review exclusion simultaneously reduces risk scores
  • AI coding and revenue cycle software vendors — BCBSA targets their output ($2.33B in potentially AI-inflated billing); CMS targets their input

Who Wins

  • Prospective, encounter-based risk adjustment platforms — companies like Vatica Health (Frazier Healthcare Partners) that tie coding to delivered services
  • Compliance and audit firms — RADV audit activity expanding, CMS now permits extrapolation of findings across populations
  • PE sponsors with clean, encounter-based revenue models who can document the distinction before LPs ask
The strongest counter: this is regulatory theater and the industry will negotiate phase-in timelines that extend well beyond any single fund's exit window. Possible. But the mechanism elimination — not the rate — is the irreversible change. Phase-in buys time; it doesn't restore the revenue architecture.

Portfolio Exposure Audit: April 6 Deadline

SGA can identify which portfolio companies have material revenue dependence on chart review-derived risk scoring, disaggregate encounter-based vs. retrospective coding margin, and model three CMS final rule scenarios. Retainer clients receive pre-publication analysis of the April 6 final rule within 24 hours of release.

[email protected]

Connected Signals